Zhejiang Xianju Pharmaceutical Co Ltd
Zhejiang Xianju Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid raw materials and preparations in China and internationally. The company offers gynecological, anesthesia, respiratory, dermatology, generic drug, and other products; active pharmaceutical ingredients (API), such as corticosteroids, sex hormone, progestero… Read more
Zhejiang Xianju Pharmaceutical Co Ltd (002332) - Net Assets
Latest net assets as of September 2025: CN¥6.03 Billion CNY
Based on the latest financial reports, Zhejiang Xianju Pharmaceutical Co Ltd (002332) has net assets worth CN¥6.03 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.26 Billion) and total liabilities (CN¥1.24 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.03 Billion |
| % of Total Assets | 82.96% |
| Annual Growth Rate | 16.26% |
| 5-Year Change | 28.5% |
| 10-Year Change | 173.55% |
| Growth Volatility | 41.09 |
Zhejiang Xianju Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Zhejiang Xianju Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Xianju Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual net assets of Zhejiang Xianju Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.89 Billion | +1.00% |
| 2023-12-31 | CN¥5.83 Billion | +5.86% |
| 2022-12-31 | CN¥5.51 Billion | +11.38% |
| 2021-12-31 | CN¥4.94 Billion | +7.91% |
| 2020-12-31 | CN¥4.58 Billion | +49.82% |
| 2019-12-31 | CN¥3.06 Billion | +12.85% |
| 2018-12-31 | CN¥2.71 Billion | +13.59% |
| 2017-12-31 | CN¥2.39 Billion | +6.66% |
| 2016-12-31 | CN¥2.24 Billion | +3.92% |
| 2015-12-31 | CN¥2.15 Billion | +75.30% |
| 2014-12-31 | CN¥1.23 Billion | +3.89% |
| 2013-12-31 | CN¥1.18 Billion | -1.71% |
| 2012-12-31 | CN¥1.20 Billion | +4.26% |
| 2011-12-31 | CN¥1.15 Billion | +2.87% |
| 2010-12-31 | CN¥1.12 Billion | +1.93% |
| 2009-12-31 | CN¥1.10 Billion | +171.28% |
| 2008-12-31 | CN¥405.55 Million | +1.18% |
| 2007-12-31 | CN¥400.83 Million | +2.52% |
| 2006-12-31 | CN¥390.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Xianju Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3951.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.63 Billion | 44.97% |
| Common Stock | CN¥989.20 Million | 16.93% |
| Other Components | CN¥2.23 Billion | 38.10% |
| Total Equity | CN¥5.84 Billion | 100.00% |
Zhejiang Xianju Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Xianju Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CS Wind Corp
KO:112610
|
$963.94 Million |
|
Etn. Fr. Colruyt NV
F:EFC1
|
$964.29 Million |
|
Guangdong Alpha Animation and Culture Co Ltd
SHE:002292
|
$964.40 Million |
|
BORR DRILLING NEW DL -10
F:B2W
|
$965.06 Million |
|
DISTRIBUTION SOL.GRP.DL 1
F:LW2
|
$963.46 Million |
|
Kidswant Children Products Co.Ltd.
SHE:301078
|
$963.40 Million |
|
Sinodata Co Ltd
SHE:002657
|
$963.37 Million |
|
Nancal Energy-Saving Tech Co
SHG:603859
|
$963.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Xianju Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,786,121,230 to 5,843,503,305, a change of 57,382,075 (1.0%).
- Net income of 397,179,000 contributed positively to equity growth.
- Dividend payments of 298,191,071 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥397.18 Million | +6.8% |
| Dividends Paid | CN¥298.19 Million | -5.1% |
| Other Changes | CN¥-41.61 Million | -0.71% |
| Total Change | CN¥- | 0.99% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Xianju Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.74x to 1.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.62 | CN¥9.11 | x |
| 2007-12-31 | CN¥0.65 | CN¥9.11 | x |
| 2008-12-31 | CN¥0.65 | CN¥9.11 | x |
| 2009-12-31 | CN¥1.89 | CN¥9.11 | x |
| 2010-12-31 | CN¥1.43 | CN¥9.11 | x |
| 2011-12-31 | CN¥1.46 | CN¥9.11 | x |
| 2012-12-31 | CN¥1.50 | CN¥9.11 | x |
| 2013-12-31 | CN¥1.53 | CN¥9.11 | x |
| 2014-12-31 | CN¥1.57 | CN¥9.11 | x |
| 2015-12-31 | CN¥2.68 | CN¥9.11 | x |
| 2016-12-31 | CN¥2.44 | CN¥9.11 | x |
| 2017-12-31 | CN¥2.62 | CN¥9.11 | x |
| 2018-12-31 | CN¥2.88 | CN¥9.11 | x |
| 2019-12-31 | CN¥3.21 | CN¥9.11 | x |
| 2020-12-31 | CN¥4.49 | CN¥9.11 | x |
| 2021-12-31 | CN¥4.88 | CN¥9.11 | x |
| 2022-12-31 | CN¥5.52 | CN¥9.11 | x |
| 2023-12-31 | CN¥5.86 | CN¥9.11 | x |
| 2024-12-31 | CN¥5.89 | CN¥9.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Xianju Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.80%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.93%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.20x
- Recent ROE (6.80%) is below the historical average (10.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 13.67% | 6.47% | 0.78x | 2.72x | CN¥13.29 Million |
| 2007 | 17.21% | 6.69% | 0.92x | 2.78x | CN¥27.08 Million |
| 2008 | 17.02% | 5.74% | 0.98x | 3.02x | CN¥26.82 Million |
| 2009 | 8.22% | 6.96% | 0.68x | 1.74x | CN¥-19.26 Million |
| 2010 | 10.86% | 8.01% | 0.82x | 1.65x | CN¥9.55 Million |
| 2011 | 11.87% | 7.87% | 0.84x | 1.80x | CN¥20.95 Million |
| 2012 | 10.35% | 6.05% | 0.82x | 2.10x | CN¥4.10 Million |
| 2013 | 5.24% | 2.62% | 0.84x | 2.38x | CN¥-55.11 Million |
| 2014 | 4.67% | 2.29% | 0.88x | 2.31x | CN¥-64.67 Million |
| 2015 | 4.98% | 4.30% | 0.72x | 1.61x | CN¥-107.47 Million |
| 2016 | 6.57% | 5.84% | 0.69x | 1.63x | CN¥-76.36 Million |
| 2017 | 8.78% | 7.24% | 0.56x | 2.18x | CN¥-28.70 Million |
| 2018 | 11.45% | 8.32% | 0.67x | 2.07x | CN¥38.20 Million |
| 2019 | 13.95% | 11.07% | 0.64x | 1.98x | CN¥116.22 Million |
| 2020 | 11.35% | 12.55% | 0.59x | 1.54x | CN¥60.02 Million |
| 2021 | 12.82% | 14.21% | 0.65x | 1.39x | CN¥136.40 Million |
| 2022 | 13.73% | 17.11% | 0.65x | 1.23x | CN¥203.67 Million |
| 2023 | 9.73% | 13.66% | 0.59x | 1.21x | CN¥-15.53 Million |
| 2024 | 6.80% | 9.93% | 0.57x | 1.20x | CN¥-187.17 Million |
Industry Comparison
This section compares Zhejiang Xianju Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Xianju Pharmaceutical Co Ltd (002332) | CN¥6.03 Billion | 13.67% | 0.21x | $963.47 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |